Clostridium difficile infection (CDI) is one of the most common causes of healthcare-associated infections but an even bigger problem for the aging population. Advanced age leads to higher incidence, higher mortality, and higher recurrences. In our study, recently published in the Journal of Infectious Diseases, we investigated the effect of aging on CDI using a mouse model. We were able to demonstrate that aging leads to worse clinical outcomes, as well as lead to changes in microbiota composition and lower antibody production against C. difficile toxin A, but not toxin B. An association between advanced age and lower antibody production against C. difficile is a new finding which would explain the effect of aging on CDI outcome. Vancomycin, an anti-C. difficile antibiotic, led to similar changes in antibody response, suggesting a connection between microbiome and antibody response in the context of aging, which would require a much more nuanced look at the treatment of CDI.
- About
- Education
- Research
- Research Departments
- Research Offices
- Research Centers
- Cancer Center
- Cancer Research
- Cardiovascular Research Center
- Carter Immunology Center
- Center for Behavioral Health & Technology
- Center for Brain Immunology & Glia
- Center for Diabetes Technology
- Center for Immunity, Inflammation & Regenerative Medicine
- Center for Public Health Genomics
- Center for Membrane & Cell Physiology
- Center for Research in Reproduction
- Myles H. Thaler Center for AIDS & Human Retrovirus Research
- Child Health Research Center (Pediatrics)
- Division of Perceptual Studies
- Research News: The Making of Medicine
- Research Core Facilities
- Other Research Programs
- Policies & Guidelines
- Clinical
- Community
- Diversity
- News
Comments